• Explore /
  • Poster
  • / First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.

First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.

Abstract Poster

Authors

null

Yeon Hee Park

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Yeon Hee Park , Hee Kyung Ahn , Ji-Yeon Kim , Jin Seok Ahn , Young-Hyuck Im , Seol-Hee Kim , Sunbae Lee , HYE-SHIN CHUNG , Soon Jae Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Immunoconjugates (non-IO)

Clinical Trial Registration Number

NCT03281824

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3551)

DOI

10.1200/JCO.2020.38.15_suppl.3551

Abstract #

3551

Poster Bd #

281

Abstract Disclosures

Similar Posters

First Author: Richard D. Kim

First Author: Alexander I. Spira

First Author: Susanna Varkey Ulahannan

First Author: Jie Wang